Compare Stocks → RSVP: Charles Payne’s Cash Flow Workshop (From Unstoppable Prosperity) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:TCDA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeTCDATricida$0.13$0.09▼$13.85$6.01M0.2217.62 million shs31.13 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceTCDATricida0.00%0.00%0.00%0.00%0.00%RSVP: Charles Payne’s Cash Flow Workshop (Ad)Are you ready to find untapped value in the stocks you already own… Without selling a single share… Then you need to know these Cash Flow Trade Strategies.Register For Free Now!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationTCDATricidaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceTCDATricidaN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookTCDATricidaN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateTCDATricida-$176.57M-$2.36N/AN/AN/AN/AN/A-103.81%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthTCDATricidaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioTCDATricidaN/A4.874.87OwnershipInstitutional OwnershipCompanyInstitutional OwnershipTCDATricidaN/AInsider OwnershipCompanyInsider OwnershipTCDATricida35.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableTCDATricida5755.67 million35.85 millionNot OptionableCUV, TCDA, and RHK HeadlinesSourceHeadlinePatrick G Enright's Net Worthbenzinga.com - May 5 at 8:15 PMSierraConstellation Partners Receives Industry Recognition for Work with Tricidafinance.yahoo.com - February 6 at 10:02 AMTricida Inc (TCDAQ)es.investing.com - January 13 at 10:29 AMEmerging Therapies in the Treatment of Clostridium difficile-Associated Diseasemedscape.com - May 30 at 8:27 AMVaniam Group Hires Paula Franson to Lead Clinical Strategy & Solutions - Yahoo Financenews.google.com - April 18 at 12:45 AMMetabolic Acidosis Market to Witness Growth by 2032, Estimates ... - Digital Journalnews.google.com - April 17 at 7:44 PMReal-time PCR as a Diagnostic Tool for Bacterial Diseasesmedscape.com - April 12 at 11:47 PMChronic Kidney Disease Drugs Market Expected To Propel Market ... - Digital Journalnews.google.com - April 10 at 8:38 AMChronic Kidney Disease Drugs Market Huge Growth in Future ... - Digital Journalnews.google.com - April 6 at 7:54 AMTricida Heading For Ch. 11 Confirmation Fight With Creditors - Law360news.google.com - March 24 at 11:19 PMAlicia Dixon Joins COPILOT Provider Support Services as VP of Strategy Development & Execution - Yahoo Financenews.google.com - March 14 at 3:50 PMAlicia Dixon Joins COPILOT Provider Support Services as VP of ... - Yahoo Financenews.google.com - March 14 at 10:49 AMTricida Heads To Ch. 11 Mediation Over Creditor Plan Issues - Law360news.google.com - March 6 at 10:59 PMTroubled Adamis To Merge With Private DMK, Focus On ... - Scripnews.google.com - March 1 at 12:17 PMRelease Opt Out Trips Up Tricida Ch. 11 Disclosure Approval - Law360news.google.com - February 27 at 8:43 PMRenibus Buys Tricida's Kidney Drug Veverimer In Ch. 11 Sale - Law360news.google.com - February 21 at 8:22 PMSTONEHILL CAPITAL MANAGEMENT LLC Buys 2, Sells 3 in 4th ... - GuruFocus.comnews.google.com - February 18 at 1:53 AMTop 5 4th Quarter Trades of ORBIMED ADVISORS LLC - GuruFocus.comnews.google.com - February 18 at 1:53 AMTricida, Inc. (TCDA) Stock Historical Prices & Data - Yahoo Financefinance.yahoo.com - February 14 at 7:22 PMRising Serum Bicarbonate Lowers CKD Progression Risk in ... - Renal and Urology Newsnews.google.com - February 8 at 7:43 AMFirm Retention Summary: Tricida Inc.wsj.com - February 3 at 3:38 PMTricida's Chapter 11 Liquidation – Global Legal Chronicle - Global Legal Chroniclenews.google.com - January 29 at 8:47 AMTricida Gets OK To Seek Stalking Horse For Ch. 11 Auction - Law360news.google.com - January 26 at 6:43 PMWeak Fundamental Momentum Drags Tricida Inc. (TCDA) Lower - Marketing Sentinelnews.google.com - January 24 at 2:09 PMCompany DescriptionsTricidaNASDAQ:TCDATricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
